Navigation Links
Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting
Date:11/29/2007

CAMBRIDGE, England, November 29 /PRNewswire/ -- Astex Therapeutics Ltd. today announced that data on its drug candidates AT9283, AT7519 and AT9311 will be presented at the American Society of Hematology's 49th Annual Meeting and Exposition, 8-11th December 2007, at the Georgia World Congress Center, Atlanta, Georgia.

AT9283 is an inhibitor of the kinases Aurora A, Aurora B, JAK2, BCR-Abl and Flt-3. There is strong evidence for an important role of each of these kinases in the development or progression of a variety of cancers. AT9283 is currently being investigated in three multi-centre clinical trials, including a Phase I/II study in patients with refractory haematological malignancies.

AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs), currently in two multi-centre Phase 1 clinical trials.

AT9311 (also known as NVP-LCQ195) is also an inhibitor of CDKs, but with a pharmacological profile that is markedly different from that of AT7519. Astex is developing AT9311 in collaboration with Novartis.

Astex discovered all of these compounds using its proprietary fragment-based drug discovery platform Pyramid(TM).

"Astex has discovered and is developing a number of products that may have promise in the treatment of a wide range of life-threatening haematological diseases. Together with investigators from the M.D. Anderson Cancer Center and the UAB Comprehensive Cancer Center, we are reporting for the first time that one of these, AT9283, has already shown early signs of clinical efficacy as a single agent in the treatment of advanced refractory AML and CML," said Harren Jhoti, Chief Scientific Officer and Executive Vice President of Astex.

Hagop Kantarjian, Chairman of the Department of Leukemia at M.D. Anderson, Principal Investigator in the Phase I/II study of AT9283, said, "We see preliminary evidence of the anti-leukemic activity of AT9283 at well-tolerated doses in patients with relapsed and refra
'/>"/>

SOURCE Astex Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KGI Elects Three New Members to Board of Trustees
2. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
3. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
4. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
5. European Union has Three-Speed Healthcare System - Many Countries Lagging in Reform
6. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. Pharmasset to Present at Three Investor Conferences in November 2007
9. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
10. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
11. Gen-Probe to Webcast Three Upcoming Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 E-QURE Corp. ... of its Bio-electrical Signal Therapy device ("BST Device"), a ... hard to heal chronic wounds, today announced that the ... an Israeli distributor specializing in medical devices, for the ... Chemipal is a 70 years old, sales, marketing and ...
(Date:8/3/2015)... WA (PRWEB) , ... August 03, 2015 , ... ... and TLD5000 diaphragm vacuum pumps to its comprehensive line of analytical laboratory equipment. ... steel valves, these versatile pumps provide a chemically resistant and maintenance-free solution for ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud ... partially hydrolyzed gluten in foods, has been accepted by AOAC International as Official ... Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific ...
(Date:7/30/2015)... TX, USA (PRWEB) , ... July 30, 2015 ... ... and microsystems, has appointed Francois Vieillard as Sales & Marketing Director. , ... positions, Francois Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Sterlitech Launches New Line of Vacuum Pumps 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... Company posts record quarterly revenues of $27.2 million, ... CRY ),a biomaterials, medical device and tissue ... quarter of 2008 increased 18 percent to,$27.2 million ... of 2007.,Excluding orthopaedic tissue processing revenues of $297,000 ...
... 31 Alsius Corporation,(Nasdaq: ALUS ), the ... critically ill patients, today,announced that it will hold ... results and provide a corporate update. Bill Worthen,president ... 1:30 p.m. Pacific Time,(4:30 p.m. Eastern Time) on ...
... Including Industrial ... ... Bioscience (Nasdaq:,PURE) today announced an agreement with DuraBan International ... DuraBan,s DuraClean(TM) brand., (Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO ), ...
Cached Biology Technology:CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 2CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 3CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 4CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 5CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 6CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 7CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 8CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 9CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 10CryoLife's Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007 11Alsius Corporation to Host Second Quarter 2008 Financial Results Conference Call on August 7 2PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant 2PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant 3PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant 4
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/13/2015)... Conn. , Jul. 13, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/188684 for ... achieves another new convenient and secure method to ... new, innovative payment methods, introduced with its groundbreaking ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... Washington, D.C. -- Plant science is key to addressing the ... Carnegie,s David Ehrhardt and Wolf Frommer. In a Perspective published ... that the development of new technology is key to transforming ... Plants serve as the conduit of energy into the biosphere, ...
... Freshwater ecosystems in northern regions are home to significantly ... to evidence that regions with vanishing waters contain unique ... -- which are actually tiny crustaceans -- comes from ... in the journal Zootaxa . The researchers ...
... WASHINGTON -- The exhaust fumes from gasoline vehicles contribute ... air pollution-secondary organic aerosols (SOA)-than those from diesel ,vehicles, ... Cooperative Institute for Research in ,Environmental Sciences (CIRES), NOAA,s ... "The surprising result we found was that it wasn,t ...
Cached Biology News:The future of plant science - a technology perspective 2Unexpected crustacean diversity discovered in northern freshwater ecosystems 2AGU: Gasoline worse than diesel when it comes to some types of air pollution 2
EPA II Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... its SpliceArray service, ExonHit can design custom ... with your gene list. Proprietary algorithms ... design microarray probes from high quality, spliced ... splice event contained in a custom SpliceArray ...
... DX's sensitivity of DNA detection has been improved. ... an agarose gel can be detected > 20 ... be purified by organic solvent extraction or with ... worked well.) DNA excised from agarose gel ...
... The RapidTrace SPE Workstation is a modular, ... extraction platform. Utilizing 1ml or 3ml industry ... up to 100 samples in less than ... loaded with 10 cartridges, and up to ...
Biology Products: